Back to results

RSV Study in Adults 60 to 75 Years of Age

Primary Purpose

RSV Infection

Status

Completed

Phase

Not Applicable

Locations

United Kingdom

Study Type

Interventional

Intervention

Challenge virus RSV-A Memphis 37b

About this trial

This is an interventional basic science trial for RSV Infection

Eligibility Criteria

60 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria (non-exhaustive list):

Healthy subjects aged 60 to 75 years
Able to give informed consent
A total body weight ≥ 50 kg and Body Mass Index (BMI) ≥ 18 kg/m2 and ≤ 33 kg/m2.
In good health with no history of major medical conditions, or clinically significant test abnormalities that will interfere with subject safety as determined by the Investigator at screening evaluation
Documented medical history either prior to entering the study and/or following medical history review by the Investigator at screening.
Serum IgA result within normal range at screening.
Subjects meeting the contraception criteria of the study.

Exclusion Criteria (non-exhaustive list):

Subjects who have smoked ≥ 10 pack years (or 20 cigarettes a day for 10 years). Of those subjects that have smoked less than 10 pack years at any time, a subject will be excluded, if in the last year, he/she has smoked any number of cigarettes in the last month and/or they have used tobacco in any form or other nicotine-containing products in any form.
Subjects who smoked in the last month prior to the study
Females who are breastfeeding, have been pregnant within 6 months prior to the study, or have a positive pregnancy test.
History of clinically significant or major disease that, in the opinion of the Investigator, may interfere with a subject completing the study and necessary investigations.
A forced expiratory volume in 1 second (FEV1) < 80% predicted.
Twelve-lead ECG recording with clinically relevant abnormalities.
Positive HIV, Hep A, B or C test.
Confirmed positive test for drugs of abuse.
Presence of fever prior to the challenge.
Evidence of vaccinations within the 4 weeks prior to the planned date of enrolment, or intention to receive any vaccination before the last scheduled visit of the study.
Those employed or immediate relatives of those employed at hVIVO.
Receipt of blood or blood products, or loss (including blood donations) of 470 mL or more of blood during the 3 months prior to the planned date of enrolment.
Receipt of systemic glucocorticoids or systemic antiviral drugs within 6 months prior to the planned date of enrolment.
History or currently active symptoms suggestive of upper or lower respiratory tract infection within 6 weeks prior to enrolment.
Any clinically significant history of large nosebleeds.
Any significant abnormality altering the anatomy of the nose.
History of significant/severe wheeze, respiratory symptoms resulting in hospitalisation, or known bronchial hyperreactivity to viruses.
History of anaphylaxis-and/or severe allergic reaction.
Use or anticipated use during the conduct of the study of concomitant medications.
Resident of nursing home and other long-term care facilities or with close or household contact with vulnerable people for approximately 2 weeks following discharge from unit.
History or presence of alcohol addiction.
Any other finding that, in the opinion of the Investigator, deems the subject unsuitable for the study.
Subjects with no detectable antibody to the challenge virus.

Sites / Locations

hVIVO Services Limited

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Open Label Pilot

Arm Description

Open Label Pilot Study. All subjects will receive the viral challenge inoculum.

Outcomes

Primary Outcome Measures

Number of routine clinical assessment abnormalities reported as adverse events.

Multiple safety clinical parameters will be used for safety evaluation: Vital signs parameters (systolic blood pressure (mmHg), diastolic blood pressure (mmHg), respiratory rate (breaths per minute), heart rate (beats per minute) and SpO2 (%) Tympanic temperature (deg C) Spirometry parameters (FEV1(absolute), FEV1(% predicted), Forced vital capacity (FVC) (absolute), FVC (% predicted), FEV1/FVC ratio (absolute), FEV1/FVC ratio (% predicted) ECG parameters (Heart Rate (beats/min), PR interval (msec), QRS duration (msec), QT interval (msec), QTc interval (msec), QTcB interval (msec), QTcF interval (msec) and RR interval (msec)) Physical examination (complete examination and directed examination assessments).

Number of safety laboratory assessment abnormalities reported as adverse events.

Haematology: platelet count, WBC count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, reticulocyte count, reticulocyte count [ each reported in 10^9/L]; RBC count (10^12/L), haemoglobin (g/L), haematocrit (%), MCV (fL), MCH (PG), MCHC (g/L), Haemoglobin A1c Biochemistry: sodium, potassium, glucose, chloride, bicarbonate, calcium, inorganic phosphate, urea, total cholesterol [each reported in mmol/L]; uric acid, creatinine, total bilirubin, indirect bilirubin, direct bilirubin [each reported in umol/L]; serum albumin (g/L), total protein (g/L), blood urea nitrogen (mg/dL), CRP (mg/L), GGT (IU/L), ALP (IU/L), ALT (IU/L), LDH (IU/L), AST (IU/L), urea (mmol/L), total cholesterol (mmol/L), Estimated Glomerular Filtration Rate. Coagulation: PT (secs), APTT (secs) Cardiac Enzymes: creatine kinase (IU/L), troponin T (ng/L) Urinalysis: colour, specific gravity, appearance, pH, blood, glucose, leukocytes, ketones, nitrite, protein, urobilinogen, bilirubin.

Number of subjects with study related Adverse Events (AEs)

use of concomitant medications frequency and severity of AEs.

Secondary Outcome Measures

Viral loads/shedding measurement following inoculation with RSV

The AUC of RSV-A Memphis 37b viral load measured in nasopharyngeal swabs by qPCR (log10 copies/mL units) and by cell base infectivity assay (log10 copies/mL units).

Duration of viral shedding.

The time (in hours) from first detectable viral shedding to first undetectable viral shedding.

Measurement of the total mucus weight produced.

Total weight of nasal discharge (grams).

Measurement of symptoms severity by self reported symptoms diary cards.

Symptoms are recorded on a grading scale of 0 to 3.

Measurement of the peak tympanic temperature.

Time of the highest recorded tympanic temperature.

Number and percentage of subjects with confirmed RSV infection.

Confirmed infection is measured by the presence of viral shedding in nasopharyngeal swabs.

Number and percentage of subjects with Upper and Lower Respiratory Tract Infection (URTI and LRTI)

URTI and LRTI are evaluated from Symptom Diary Cards and Physical Examination.

Full Information

NCT ID

NCT03919591

First Posted

April 1, 2019

Last Updated

October 10, 2019

Sponsor

Hvivo

Collaborators

GlaxoSmithKline

1. Study Identification

Unique Protocol Identification Number

NCT03919591

Brief Title

RSV Study in Adults 60 to 75 Years of Age

Official Title

An Exploratory Pilot Study to Evaluate the Clinical Safety and Virologic Profile of an Experimental RSV Infection in Adults 60 to 75 Years of Age

Study Type

Interventional

2. Study Status

Record Verification Date

October 2019

Overall Recruitment Status

Completed

Study Start Date

March 12, 2019 (Actual)

Primary Completion Date

July 11, 2019 (Actual)

Study Completion Date

July 11, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Hvivo

Collaborators

GlaxoSmithKline

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The purpose of this study is to infect healthy volunteers aged 60-75 years old with Respiratory Syncytial Virus (RSV) to confirm how safe and well tolerated the use of an experimental RSV virus is in a population that has not previously received the virus. Additionally, this study will also look at various components of the volunteers' blood, the lining of their noses and other samples in order to measure the effects of the virus on the body, in particularly the immune system before, during and after viral infection.

Detailed Description

RSV is a common virus that affects all human age groups. Typical RSV illness is identified by symptoms such as runny nose, stuffy nose, sneezing, sore throat, earache, malaise or tiredness, cough, shortness of breath, headache, muscle ache, joint ache or stiffness, chilliness and feverishness. RSV spreads easily from person to person through the eyes, nose or mouth when droplets containing the virus, such as those from coughing or sneezing, are inhaled or passed to others. Adults with risk factors, like another illness or disease, may experience an RSV illness that is more severe or lasts longer. RSV may also start a worsening of health in frail adults, people with weak immune systems, and those with chronic cardio-pulmonary disease. No treatment or vaccine to treat or prevent RSV disease is available in the UK. Vaccination against RSV has the potential to be a highly beneficial and effective approach to reduce RSV disease in older adults as well as other high-risk adult and paediatric populations. The use of RSV human viral challenge model provides an important tool to evaluate the effectiveness of new RSV vaccines. Specifically, a RSV human viral challenge in 60 to 75-year-old individuals would enable measuring the effectiveness of RSV vaccines in a population that is thought to be less responsive to vaccines than the 18-45-year-old population. The purpose of this study is to infect up to 74 healthy subjects aged 60 to 75 years old with RSV in a controlled quarantine environment to confirm how safe and well tolerated the use of an experimental RSV virus infection is in a population that has not previously received the virus. Additionally, the investigators will also look at various components of the subjects' blood, the lining of their noses and other samples in order to measure the effects of the virus on the body, in particularly the immune system before, during and after viral infection. The study will consist of 3 phases: 1) Screening, 2) Quarantine and 3) Follow-up. The enrolment of the subjects will be staggered with safety data reviews performed between groups. Each volunteer will be in the study for approximately 3 months from screening to their last scheduled clinic visit.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

RSV Infection

7. Study Design

Primary Purpose

Basic Science

Study Phase

Not Applicable

Interventional Study Model

Single Group Assignment

Model Description

Each subject will receive one titre of the Challenge Virus intranasally.

Masking

None (Open Label)

Allocation

N/A

Enrollment

24 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Open Label Pilot

Arm Type

Other

Arm Description

Open Label Pilot Study. All subjects will receive the viral challenge inoculum.

Intervention Type

Other

Intervention Name(s)

Challenge virus RSV-A Memphis 37b

Intervention Description

Each subject will receive one titre of virus, which will be up to approximately 4.5 log10 PFU.

Primary Outcome Measure Information:

Title

Number of routine clinical assessment abnormalities reported as adverse events.

Description

Time Frame

Safety data collected throughout the study (estimated 4 month).

Title

Number of safety laboratory assessment abnormalities reported as adverse events.

Description

Time Frame

Safety data collected throughout the study (estimated 4 month).

Title

Number of subjects with study related Adverse Events (AEs)

Description

use of concomitant medications frequency and severity of AEs.

Time Frame

Safety data collected throughout the study (estimated 4 month).

Secondary Outcome Measure Information:

Title

Viral loads/shedding measurement following inoculation with RSV

Description

The AUC of RSV-A Memphis 37b viral load measured in nasopharyngeal swabs by qPCR (log10 copies/mL units) and by cell base infectivity assay (log10 copies/mL units).

Time Frame

Virology and clinical data collected throughout the study (estimated 4 month).

Title

Duration of viral shedding.

Description

The time (in hours) from first detectable viral shedding to first undetectable viral shedding.

Time Frame

Virology and clinical data collected throughout the study (estimated 4 month)

Title

Measurement of the total mucus weight produced.

Description

Total weight of nasal discharge (grams).

Time Frame

Virology and clinical data collected throughout the study (estimated 4 month).

Title

Measurement of symptoms severity by self reported symptoms diary cards.

Description

Symptoms are recorded on a grading scale of 0 to 3.

Time Frame

Symptom Diary Cards data is collected throughout the quarantine period (estimated 15 days)

Title

Measurement of the peak tympanic temperature.

Description

Time of the highest recorded tympanic temperature.

Time Frame

Temperature data is collected from day 0 to day 12.

Title

Number and percentage of subjects with confirmed RSV infection.

Description

Confirmed infection is measured by the presence of viral shedding in nasopharyngeal swabs.

Time Frame

Virology data collected throughout the study (estimated 4 month)

Title

Number and percentage of subjects with Upper and Lower Respiratory Tract Infection (URTI and LRTI)

Description

URTI and LRTI are evaluated from Symptom Diary Cards and Physical Examination.

Time Frame

Clinical data collected throughout the study (estimated 4 month)

10. Eligibility

Sex

All

Minimum Age & Unit of Time

60 Years

Maximum Age & Unit of Time

75 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria (non-exhaustive list): Healthy subjects aged 60 to 75 years Able to give informed consent A total body weight ≥ 50 kg and Body Mass Index (BMI) ≥ 18 kg/m2 and ≤ 33 kg/m2. In good health with no history of major medical conditions, or clinically significant test abnormalities that will interfere with subject safety as determined by the Investigator at screening evaluation Documented medical history either prior to entering the study and/or following medical history review by the Investigator at screening. Serum IgA result within normal range at screening. Subjects meeting the contraception criteria of the study. Exclusion Criteria (non-exhaustive list): Subjects who have smoked ≥ 10 pack years (or 20 cigarettes a day for 10 years). Of those subjects that have smoked less than 10 pack years at any time, a subject will be excluded, if in the last year, he/she has smoked any number of cigarettes in the last month and/or they have used tobacco in any form or other nicotine-containing products in any form. Subjects who smoked in the last month prior to the study Females who are breastfeeding, have been pregnant within 6 months prior to the study, or have a positive pregnancy test. History of clinically significant or major disease that, in the opinion of the Investigator, may interfere with a subject completing the study and necessary investigations. A forced expiratory volume in 1 second (FEV1) < 80% predicted. Twelve-lead ECG recording with clinically relevant abnormalities. Positive HIV, Hep A, B or C test. Confirmed positive test for drugs of abuse. Presence of fever prior to the challenge. Evidence of vaccinations within the 4 weeks prior to the planned date of enrolment, or intention to receive any vaccination before the last scheduled visit of the study. Those employed or immediate relatives of those employed at hVIVO. Receipt of blood or blood products, or loss (including blood donations) of 470 mL or more of blood during the 3 months prior to the planned date of enrolment. Receipt of systemic glucocorticoids or systemic antiviral drugs within 6 months prior to the planned date of enrolment. History or currently active symptoms suggestive of upper or lower respiratory tract infection within 6 weeks prior to enrolment. Any clinically significant history of large nosebleeds. Any significant abnormality altering the anatomy of the nose. History of significant/severe wheeze, respiratory symptoms resulting in hospitalisation, or known bronchial hyperreactivity to viruses. History of anaphylaxis-and/or severe allergic reaction. Use or anticipated use during the conduct of the study of concomitant medications. Resident of nursing home and other long-term care facilities or with close or household contact with vulnerable people for approximately 2 weeks following discharge from unit. History or presence of alcohol addiction. Any other finding that, in the opinion of the Investigator, deems the subject unsuitable for the study. Subjects with no detectable antibody to the challenge virus.

Facility Information:

Facility Name

hVIVO Services Limited

City

London

ZIP/Postal Code

E1 2AX

Country

United Kingdom

12. IPD Sharing Statement

Plan to Share IPD

IPD Sharing Plan Description

Anonymised data might be shared with hVIVO's research partners

Learn more about this trial

RSV Study in Adults 60 to 75 Years of Age

We'll reach out to this number within 24 hrs